Cartesian's Descartes-08 heads to Phase 3 MG readout as only such trial in class
The AURORA trial is the sole Phase 3 program pairing a BCMA-directed CAR-T with myasthenia gravis, leaving no direct precedent for what its MG-ADL result should look like.
Executive Summary
- Cartesian Therapeutics is running the only Phase 3 trial anywhere that pairs a BCMA-directed CAR-T therapy with myasthenia gravis, meaning the coming readout has no same-class precedent to be measured against.
- The trial design was locked in through a formal FDA agreement before enrollment began, narrowing the room for the kind of design dispute that often clouds a first-of-its-kind readout.
- A recent status flip and completion-date shift early in the trial's life reflect normal pre-enrollment registry housekeeping, not a signal about the trial's conduct today.
- A registration-directed BLA filing is tied to this result on a stated mid-2027 timeline, so the readout will determine whether the sponsor's own regulatory sequence proceeds as planned.
The trial and its bar
AURORA (NCT06799247) is a randomized, placebo-controlled Phase 3 study enrolling 100 adults with acetylcholine receptor antibody-positive generalized myasthenia gravis, with one experimental arm against one placebo arm. Its primary endpoint is change in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, a patient-reported functional scale used across the class. The trial's design carries a Special Protocol Assessment agreement with the FDA reached in January 2025, which locks the endpoint and analysis population ahead of the readout. Cartesian said it expects topline data in the first quarter of 2027, with a BLA filing planned for mid-2027 if the data support it. NCT06799247+1Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 ...May 26, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Registry mechanics
The trial's primary completion date moved once, from April 28, 2026 to November 30, 2026, in a single amendment recorded in February 2025, alongside a brief flip in recruitment status from Recruiting to Not yet recruiting and back within about six weeks. Both changes landed before enrollment was fully underway and the trial's amendment rate since has held at one protocol-tracked change per year, a pattern read as stable. Enrollment has not moved from its 100-patient target, a change the operational model treats as within the routine, unflagged band. NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247
Where it sits in the field
No other industry trial pairs a BCMA target with myasthenia gravis at Phase 3, or at any phase, according to competitive mapping across BCMA-targeted, myasthenia gravis, and CAR-T-modality trials. The nearest neighbors share only the CAR-T modality and the indication, not the BCMA target: Kyverna Therapeutics' KYV-101 and Cabaletta Bio's CABA-201 both target CD19 in myasthenia gravis and remain in earlier-phase testing. The broader myasthenia gravis field also includes FcRn and complement-targeted antibodies from argenx, UCB Pharma, Alexion, and Dianthus Therapeutics, all mechanistically distinct from a cell-depleting CAR-T approach. With no BCMA-CAR-T precedent to benchmark against in this indication, a placebo-adjusted MG-ADL improvement that holds up through the SPA-agreed analysis would be the result that gives this modality its first registration-stage read in the disease.
Regulatory backdrop
Descartes-08 carries both RMAT and Orphan Drug designations from the FDA for myasthenia gravis, granted in November 2025 and reiterated in company disclosures through March and May 2026. Those designations reflect the FDA's engagement with an unmet-need population and unlock more frequent agency interaction; they do not themselves indicate how the trial will read out. Cartesian's chief executive, Carsten Brunn, said the company believes Descartes-08 is the only CAR-T in autoimmune disease designed for outpatient administration without preconditioning chemotherapy, a positioning point distinct from the trial's efficacy question. CartesianCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 ...May 26, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.